Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Constituents of Carpobrotus edulis Inhibit P-Glycoprotein of MDR1-transfected Mouse Lymphoma Cells

A. MARTINS, A. VASAS, ZS. SCHELZ, M. VIVEIROS, J. MOLNÁR, J. HOHMANN and L. AMARAL
Anticancer Research March 2010, 30 (3) 829-835;
A. MARTINS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. VASAS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZS. SCHELZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. VIVEIROS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. MOLNÁR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. HOHMANN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. AMARAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lamaral@ihmt.unl.pt
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

A bioassay-guided separation protocol, including the testing of the extracts, fractions and pure compounds for their ability to inhibit P-glycoprotein (the efflux pump responsible for the multidrug resistance of the used cell line) of mouse lymphoma cells containing the human efflux pump gene MDR1, led to the isolation of seven compounds from the chloroform and ethyl acetate soluble fractions of the methanolic extract of Carpobrotus edulis. The compounds were identified by 1D, 2D NMR and MS investigations as triterpens (β-amyrin, uvaol and oleanolic acid), monogalactosyldiacylglycerol, catechin, epicatechin and procyanidin B5. Uvaol was the most effective and promising compound in the reversal of multidrug resistance in MDR mouse lymphoma cell line.

  • Carpobrotus edulis
  • Aizoaceae
  • efflux pump
  • P-glycoprotein
  • multidrug resistance

Multidrug resistance (MDR) of cancer and to bacterial infections caused by Staphylococcus aureus or Mycobacterium tuberculosis are major health problems that affect therapy. The use of compounds that reverse resistance of MDR pathologies is now a widely accepted approach for the therapy of multidrug resistance (1-3).

MDR of cancer is mainly due to efflux pumps that are overexpressed as a consequence of treatment. These efflux pumps extrude the anticancer drug before it can reach its intended target (4). Moreover, for reasons that remain unclear, these efflux systems not only extrude the drug to which the cancer has become refractory, but also many other compounds used for chemotherapy of cancer (5), hence, their MDR phenotype. It should be noted some untreated tumors are also of an MDR phenotype which results from an overexpressed intrinsic efflux pump (6). Among the 12 or so transporter proteins that make up such efflux pumps of MDR is P-glycoprotein (P-gp), an ATP-binding cassette (ABC) transporter that is coded by the gene MDR1 and which may be overexpressed intrinsically or as a consequence of chemotherapy (7). The energy of the ABC type transporters needed for their activity is derived from the hydrolysis of ATP (8). Although the molecular mechanism for the extrusion of a wide range of structurally diverse drugs remains unclear, the extrusion of drugs by P-gp can be blocked by many compounds, such as nifedipine, verapamil, quinine, chloroquine, progestogens, tamoxifen, cyclosporin A and its analogues, reserpine and tricyclic antidepressants (9, 10). However, most of these compounds are toxic at concentrations that block the P-gp pump. As an example, verapamil at a concentration of 2 mg/L blocks the P-gp pump but also produces congestive cardiac failure (11).

Plants are rich sources of new drugs for the therapy of cancer (12-14) and bacterial infections (2, 15-17). Some of the compounds derived from plants can serve as adjuvants to current chemotherapy inasmuch as they reverse MDR of cancer (18) and MDR of bacterial infections (17). One of these plants is Carpobrotus edulis; its methanolic extract has been shown to have activity against MDR cancer and MDR M. tuberculosis (19, 20). This succulent plant is very common in sandy and dune areas of Portugal and other Mediterranean countries (21, 22), coastal California (23) and South Africa. In the latter country, C. edulis is used in traditional medicine for the treatment of burns, stomach ailments, ulcerations of the mouth, toothache, oral and vaginal thrush, as well as bacterial infections, such as those affecting the lungs (tuberculosis), sinuses, and the colon (dysentery) (22, 24-27).

Previously, Ordway et al. showed that the methanolic extract of C. edulis reverses resistance of mouse lymphoma cells carying the human MDR1 gene to chemotherapeutic agents and increases the killing activity of S. aureus-infected macrophages (20). Martins et al. demonstrated that the same extract was active against MDR M. tuberculosis and methicillin-resistant S. aureus (19). Other researchers have shown that extracts of other Carpobrotus species are active against various bacteria (26). Compounds active against Bacillus subtilis, Staphylococcus epidermis, S. aureus, Streptococcus pneumonia, Moraxella catarrhalis and Pseudomonas aeruginosa have been isolated from C. edulis by Watt et al. (22). Among the identified active compounds were ferulic acid, flavonoids (rutin, hyperoside and neohesperidin) and cactichin (22).

Although the above studies were primarily restricted to activities of the extracts and compounds against bacteria, the observation of Ordway et al. that the methanolic extract demonstrated activity against MDR of cancer cells (20) spurred us to isolate and identify the active constituents of the methanolic extract of C. edulis responsible for the anti-MDR activity.

Materials and Methods

Plant material. The leaves of C. edulis (L.) N. E. Br. (Aizoaceae) were collected in November 2007 at Guincho (Sintra, Portugal). The plant was authenticated by Professor António Viveiros (Professor Emeritus of Botany, Plant Biology Department, Sciences Faculty of the University of Lisbon).

Cell cultures. Parental and MDR cell lines used in the biological assays were L5178 mouse T-cell lymphoma cells (ECACC cat. no. 87111908, U.S. FDA, Silver Spring, MD, USA) and the L5178 mouse T-cell lymphoma cells transfected with pHa MDR1/A retrovirus, as previously described (28). MDR cell lines were selected by culturing the infected cells with 60 ng/ml of colchicine to maintain the expression of the MDR phenotype (29). Both cell lines were cultured in McCoy's 5A medium supplemented with 10% heat-inactivated horse serum, L-glutamine and antibiotics (penicillin and streptomycin), at 37°C and 5% CO2 atmosphere. Medium, horse serum and antibiotics purchased from Difco, USA.

General purification procedures. For the purification, vacuum-liquid chromatography (VLC) and rotation planar chromatography (RPC) on polyamide (ICN) and on silica gel (Kieselgel GF254 15 μm; Merck, Germany) were used. Gel chromatography was carried out on Sephadex LH-20. Preparative thin layer chromatography (TLC) was performed on silica gel plates (Merck 5715; Merck). High performance liquid chromatography (HPLC) was carried out on a Waters Millipore instrument (Millipore, Waters Chromatography Division, Milliford, USA), on a LiChrospher® 100 RP-18 (10 μm) column with MeOH-H2O (3:7) as mobile phase with detection at 220 and 254 nm. Chromatographic fractions were monitored by normal phase (NP)-TLC on silica gel plates (60 F254; Merck) and reversed phase (RP)-TLC (RP-18 F254S, Merck), visualized by spraying with concentrated H2SO4, followed by heating.

Structural nuclear magnetic resonance (NMR) elucidation was carried out by extensive spectroscopic analysis, including 1D and 2D (1H-1H correlation spectroscopy (COSY), Heteronuclear Single Quantum Coherence (HSQC) and Heteronuclear Multiple Bond Correlation (HMBC)) on a Bruker Avance DRX 500 spectrometer at 500 MHz (1H) and 125 MHz (13C) (Bruker, Zurich, Switzerland). The stereochemistry of the compounds was studied by Nuclear Overhauser Effect Spectroscopy (NOESY) measurements. 1D NMR spectra were recorded. Two dimensional experiments were performed using the standard Bruker software.

Extraction. The fresh plant material of C. edulis (5 kg) was extracted with MeOH (13 l) at room temperature. The crude extract was concentrated under vacuum (Rotavapor-RE, Büchi) to 500 ml and extracted with n-hexane (1600 ml). The n-hexane was evaporated off leading fraction A. The aqueous methanolic phase was then extracted with chloroform (2.5 l). On evaporation, an organic phase residue was obtained (fraction B). Thereafter the methanol-water phase was extracted with ethyl acetate (1.2 l) which yielded a dry residue after evaporation (fraction C).

Isolation of the compounds. Fractions A and B were jointly chromatographed on a polyamide column with mixtures of H2O–MeOH (4:1, 7:3, 3:2, 1:1, 2:3, 3:7 and 1:4) as eluents. The fractions obtained with 60, 70 and 80% MeOH elutions were combined and chromatographed on silica gel, using a gradient system of n-hexane–CHCl3–MeOH (7:3:0, 3:2:0, 1:1:0, and 50:50:1), and CHCl3–MeOH–H2O (49:1:0, 9:1:0, 4:1:0 and 35:13:2). The fractions obtained with n-hexane–CHCl3–MeOH (50:50:1) and CHCl3–MeOH (49:1) were further purified on Sephadex LH-20 using MeOH as eluent. Fractions were then separated by using RPC on silica gel with n-hexane–CH2Cl2 (50:50) and increasing concentrations of MeOH (0.25, 0.5, 1, 2, 3, 5, 10 and 50, respectively) to yield compounds 1 (13.1 mg), 2 (14.3 mg) and 3 (12.4 mg) (Figue 1).

The fraction obtained from polyamide column with 50% MeOH was chromatographed on a silica gel column, described previously, using the same parameters. The fraction obtained with CHCl3–MeOH (49:1) was further purified by preparative TLC with cyclohexane–EtOAc–EtOH (30:20:2) to obtain compound 4 (10.6 mg).

The ethyl acetate fraction (fraction C) was chromatographed on a silica gel (40 g) column with a gradient system of CH2Cl2–MeOH–H2O (49:1:0, 9:1:0, 85:15:0, 4:1:0, 7:3:0 and 70:30:1), and MeOH:H2O (4:1). Fractions eluted with CH2Cl2–MeOH (85:15 and 4:1) were separated on a silica gel column using a gradient of CHCl3–MeOH (49:1 to 7:3) and the fraction eluted with CHCl3–MeOH (4:1) was further purified by RP-HPLC. As a result of this separation, compounds 5 (7.7 mg) and 6 (5.6 mg) were obtained. The fraction eluted from silica gel column with CH2Cl2–MeOH–H2O (70:30:1) was chromatographed on a Sephadex LH-20 column, then on preparative TLC plates with EtOAc–HCOOH–H2O (49:2:1; NP-TLC), and then with MeOH:H2O (1:1, RP-TLC) as developing systems, to yield compounds 5 and 6 and with AcNi:H2O: CH3COOH (30:70:0.5, RP-TLC) to yield compound 7 (3.6 mg).

Antiproliferative assay. The antiproliferative activity of the compounds against parental mouse lymphoma cells and their MDR1 transfected progeny was tested in triplicate by the MTT microplate assay previously described in detail (30).

Checker-board assay. The compounds were evaluated by the checkerboard microplate method for the study of drug interaction between the pure compound and doxorubicin on MDR cancer cells. This method is similar to the antiproliferative assay and was previously described in detail (30).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Structures of the compounds isolated from the methanolic extract of C. edulis: β-amyrin (1), oleanolic acid (2), uvaol (3), monogalactosyldiacylglycerol (MGDG) (4), catechin (5), epicatechin (6) and procyanidin B5 (7).

Flow cytometry. The activity of the fractions and pure compounds on the P-gp transporter of parental and MDR1 transfected progeny was evaluated by following the accumulation of the fluorochrome rhodamine 123 as previously described in detail (31). Compounds that inhibit the P-gp transporter cause accumulation of rhodamine 123 that would otherwise be extruded in the absence of the active compound (4). Briefly, the cells were re-suspended to a final density of 1×106 cells in 0.5 ml of serum-free McCoy's 5A medium. Each aliquot of cells was individually treated with the purified compounds dissolved in DMSO (Sigma, Germany) and incubated for 10 min, after which rhodamine 123 (Sigma) was added to each tube to yield a final concentration of 5.2 μM; the samples were then incubated for 20 min at 37°C, centrifuged at 2000 rpm for 2 min and the pellet re-suspended in 0.5 mL of PBS. The PBS washing procedure was repeated twice. The fluorescence of the samples was measured by flow cytometry (Becton Dickinson FACScan, BD, USA). Verapamil (Sanofi-Synthelabo) at 10 mg/L was used as the positive control (4).

Semi-automated fluorimetry. The modulation of P-gp activity of each compound was also assessed by the semi-automated ethidium bromide (EB) fluorometric method using a Rotor-Gene 3000™ thermocycler with real-time analysis software (Corbett Research, Sidney, Australia) as described elsewhere (32).

Results

The MeOH extract of the fresh leaves of C. edulis was extracted with n-hexane, chloroform and EtOAc. The organic phases were subjected to multiple chromatographic purification, including VLC, RPC, preparative TLC, HPLC and gel-filtration, to afford seven pure compounds (1-7). On the basis of atmospheric pressure chemical ionization–mass spectrometry (APCI-MS), electron spray ionization mass spectrometry (ESIMS), 1H-NMR, 13C-NMR, 1H-1H COSY, HSQC, HMBC and NOESY investigations, and by comparison of the spectral data with those published in the literature, the compounds were identified as β-amyrin (1) (33), oleanolic acid (2) (34), uvaol (3) (35, 36), monogalactosyldiacylglycerol (acyls=linolenoyl group; MGDG) (4) (37), catechin (5) (38, 39), epicatechin (6) (38, 39) and procyanidin B5 (7) (Figure 1) (40). To our knowledge, this is the first report on the isolation of compounds 1-7 from C. edulis.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Antiproliferative activity as shown by the 50% inhibitory concentration (IC50) of the compounds isolated from C. edulis.

The antiproliferative activity of the purified compounds on mouse lymphoma parental cells and human MDR1-transfected mouse lymphoma cells is summarized in Table I. All of the compounds reduced the proliferation of both parental and MDR1-transfected cells. However, whereas oleanolic acid and uvaol were more effective against the parental cells, MGDG and epicatechin were more effective against the MDR1-transfected cells. It should be noted that in this study, the parental cells are cancer cells and therefore, compounds that reduce the replication of these cells also merit attention.

The effect of the isolated compounds on the inhibition of P-gp and consequent accumulation of rhodamine 123 inside the cells was measured in terms of fluorescence (Fl) by flow cytometry in presence and absence of the compounds. The activity is presented as a fluorescence activity ratio (FAR), which is equal to: FAR=(FlMDR treated – FlMDR control)/(FlPAR treated – FlPAR control). FAR values are summarized in Table II. The concentration of DMSO used in the assay was 4% and corresponds to the maximum percentage of DMSO used to dissolve the compounds and thus its final concentration in the assay. The P-gp modulator verapamil was used at a concentration of 10 mg/L as the positive control. The compounds isolated in this study were devoid of any cytotoxicity at the concentrations employed (data not shown). As evident from the FAR values of Table II in comparison to the verapamil positive control, uvaol demonstrated significant inhibition of P-gp.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Fluorescence activity ratio (FAR) values for the isolated compounds at the two concentrations tested as well as of the DMSO control.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Relative fluorescence factor (RFF) values for the isolated compounds at the two concentrations tested.

The activity of the compounds isolated from C. edulis was also evaluated with the aid of the automated EB method. In this method, a compound that inhibits an efflux system extruding the fluorescent substrate EB produces an increase of fluorescence as a consequence of the build up of EB within the cell. The use of two distinct methods that evaluate efflux reinforces the significance of the inhibitory activity noted for a given compound.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Accumulation of ethidium bromide in MDR mouse lymphoma cells in the presence of A: uvaol, B: oleanolic acid and C: MGDG.

The effects of oleanolic acid, uvaol and MGDG on the accumulation of EB by the mouse lymphoma transfected with MDR1 are illustrated by Figure 2 which shows that these compounds promote the accumulation of the fluorochrome EB. These results confirm the effects of the compounds as evaluated by a totally different method, namely flow cytometry: uvaol, the most active, followed by oleanolic acid and MGDG.

The amount of fluorescence at the end of 90 minutes in the absence and presence of each compound is provided by Table III. Briefly, uvaol, the most effective compound that reversed resistance of the MDR1-transfected mouse lymphoma cells to the cytotoxic agent doxorubicin, produced the greatest degree of fluorescence, thereby indicating that this compound strongly inhibits the efflux activity of P-pg.

Because the combination of uvaol was the most active agent inhibiting the efflux activity of P-gp, the checker-board method was employed for the determination of any synergism between uvaol and doxorubicin on the replication of the MDR1-transfected mouse lymphoma cells. The checker-board method provides a FIX value that is obtained as the sum of the FIX values for each compound separately (41): FIX=FIXuvaol +FIXdoxorubicin. The FIX value of each compound is the fractional IC50 of the combined drugs divided by their individual IC50 as follow: FIXuvaol=IC50(uvaol+doxorubicin)/IC50uvaol and FIXdoxorubicin= IC50(uvaol+doxorubicin)/IC50doxorubicin. If the FIX value is equal to 1, it represents an additive effect of the two drugs that is equal to the sum of the individual effect of each of the drugs when used separately. If the FIX value is equal to any of the individual values it means that the result with the two drugs does not significantly differ from that of the most effective drug used alone. FIX values larger than 1 represent antagonism and mean that the result of the two drugs is significantly less than the additive response. Synergism corresponds to FIX values equal to or less than 0.5 (41). Uvaol in combination with doxorubicin yielded a FIX value of 0.49, suggestive of synergism.

Discussion

The results obtained in this study show that all of the compounds isolated from C. edulis have an antiproliferative effect on both cell lines. However, the antiproliferative activity of oleanolic acid, uvaol and catechin is more pronounced on the parental cell line. The antiproliferative effect of β-amyrin and epicatechin is not significantly different for the two cell lines. However, the MDR cell line is a little more sensitive to MGDG. Previous workers showed that this compound reduced the biosynthesis of cholesterol by inhibiting the human enzyme lanosterol synthase (37). This result, together with the lipophilic nature of MGDG, suggests that MGDG acts in the MDR cell line in a more specific manner.

Of the compounds isolated from C. edulis, uvaol was the most effective in inhibiting the extrusion of rhodamine 123 and EB by the MDR mouse lymphoma cells as evident from the accumulation of these P-gp substrates, demonstrated by two distinctly different methods, flow cytometry and the EB automated method, respectively. Because this compound does not produce toxicity at the concentrations employed, it may have potential as an adjuvant for the therapy of cancer that is refractory to therapy.

The other compounds isolated from C. edulis also inhibited the P-gp transporter of MDR cancer cells, but to a lesser extent than uvaol. This is the first time that the inhibitory activity of uvaol, β-amyrin, oleanolic acid and MGDG against the P-gp transporter of MDR cancer cells has been shown. Catechin, epicatechin and its derivatives, mainly found in green tea, have been isolated from other plants and were shown to act as chemopreventive (42) and anti-inflammatory agents (43), and inhibitors of gastric H+, K+-ATPase (44). We believe that these compounds are responsible for the traditional use of C. edulis for stomach problems and against different kinds of inflammations (22, 26, 27). Moreover, because these compounds have now been shown to inhibit the P-pg transporter, they may also have the capacity to inhibit other efflux pumps, such as those that are responsible for the excessive extrusion of H+ by gastric epithelial cells. Analogues of epicatechin have been shown to inhibit P-gp, but the parental compound itself has been reported to be devoid of such activity (45). This variance between our results and those of others (45) may be due to the expression of the human P-gp transporter or its location on the plasma membrane of the mouse lymphoma cell which renders it immune to the action of catechin or epicatechin. Procyanidin B5 dimmers were also demonstrated as potential chemopreventive agents against breast cancer by suppressing in situ estrogen biosynthesis (46). MDGD, catechin and its isomer epicatechin are not responsible for the reversal of MDR activity exhibited by the plant extract, since they show low FAR values.

The structural difference between uvaol and β-amyrin or oleanolic acid is the methyl group at position C-29, which seems to play an important role in the activity of this class of compounds. Further studies should be conducted in order to detail the structure activity relationship. Furthermore, members of the triterpenes group may serve as lead compounds for the synthesis of new compounds that may prove even more effective as inhibitors of P-gp than those isolated from C. edulis, hence, they may serve as adjuvants in cancer chemotherapy.

Acknowledgements

Ana Martins was supported by FCT grant SFRH/BD/19445/2004, by a short period FCG grant and by the Hungarian Research Foundation (OTKA K72771). A. Varsas acknowledges the award of a János Bolgai scholarhip from the Hungarian Academy of Sciences. We thank Anikó Váradi and Erzsébet Hadárné Berta for their precious technical contribution, Imre Ocsovszki for the flow cytometry measurements, Peter Forgo for the NMR measurements and Mária Báthori for mass spectral analyses.

Footnotes

    • Received September 16, 2009.
    • Revision received February 10, 2010.
    • Accepted February 17, 2010.
  • Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Dutta NK,
    2. Annadurai S,
    3. Mazumdar K,
    4. Dastidar SG,
    5. Kristiansen JE,
    6. Molnar J,
    7. Martins M,
    8. Amaral L
    : Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. Int J Antimicrob Agents 30: 242-249, 2007.
    OpenUrlPubMed
  2. ↵
    1. Martins M,
    2. Dastidar SG,
    3. Fanning S,
    4. Kristiansen JE,
    5. Molnar J,
    6. Pagès J-M,
    7. Schelz Z,
    8. Spengler G,
    9. Viveiros M,
    10. Amaral L
    : Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 31: 198-208, 2008.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Werle M,
    2. Takeuchi H,
    3. Bernkop-Schnurch A
    : New-generation efflux pump inhibitors. Expert Rev Clin Pharmacol 1: 429-440, 2008.
    OpenUrl
  4. ↵
    1. Molnar J,
    2. Gyémánt N,
    3. Tanaka M,
    4. Hohmann J,
    5. Bergmann-Leitner E,
    6. Molnár P,
    7. Deli J,
    8. Disiziapetris R,
    9. Ferreira MJU
    : Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr Pharm Des 12: 287-311, 2006.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ferry DR,
    2. Kerr DJ
    : Multidrug resistance in cancer. BMJ 308: 148-149, 1994.
    OpenUrlFREE Full Text
  6. ↵
    1. Shustik C,
    2. Groulx N,
    3. Gros P
    : Analysis of multidrug resistance (MDR1) gene expression in chronic lymphocytic leukaemia (CLL). Br J Haematol 79: 50-56, 1991.
    OpenUrlPubMed
  7. ↵
    1. Filipits M
    : Mechanisms of cancer: multidrug resistance. Drug Discov Today: Dis Mechan 1: 229-234, 2004.
    OpenUrl
  8. ↵
    1. Piddock LJV
    : Multidrug-resistance efflux pumps - not just for resistance. Microbiology 4: 629-636, 2006.
    OpenUrlPubMed
  9. ↵
    1. Endicott JA,
    2. Ling V
    : The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Tsuruo T,
    2. Iida H,
    3. Kitatani Y,
    4. Yokota K,
    5. Tsukagoshi S,
    6. Sakrai Yu
    : Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 44: 4303-4307, 1984.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Miller TP,
    2. Grogan TM,
    3. Dalton WS,
    4. Spier CM,
    5. Scheper RJ,
    6. Salmon SE
    : P-Glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Duarte N,
    2. Járdánházy A,
    3. Molnar J,
    4. Hilgeroth A,
    5. Ferreira MJU
    : Synergistic interaction between P-glycoprotein modulators and epirubicine on resistant cancer cells. Bioorg Med Chem 16: 9323-9330, 2008.
    OpenUrlPubMed
    1. Hohmann J,
    2. Molnar J,
    3. Rédei D,
    4. Evanics F,
    5. Forgo P,
    6. Kálmán A,
    7. Argay G,
    8. Szabó P
    : Discovery and biological evaluation of a new family of potent modulators of multidrug resistance: Reversal of multidrug resistance of mouse lymphoma cells by new natural jatrophane diterpenoids isolated from Euphorbia species. J Med Chem 45: 2425-2431, 2002.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Hohmann J,
    2. Rédei D,
    3. Forgo P,
    4. Molnar J,
    5. Dombi G,
    6. Zorig T
    : Jatrophane diterpenoids from Euphorbia mongolica as modulators of the multidrug resistance of L5128 mouse lymphoma cells. J Nat Prod 66: 976-979, 2008.
    OpenUrl
  14. ↵
    1. Gibbons S
    : Antibacterials from plants – new templates to counter bacterial resistance. Planta Med 74: L17, 2008.
    OpenUrl
    1. Gibbons S
    : Phytochemicals for baterial resistance – Strengths, weaknesses and opportunities. Planta Med 74: 594-602, 2008.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Stavri M,
    2. Piddock LJV,
    3. Gibbons S
    : Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 59: 1247-1260, 2007.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Molnar J.,
    2. Engi H.,
    3. Gyémánt N,
    4. Schelz Z,
    5. Spengler G,
    6. Ocsovszki I,
    7. Szűcs M,
    8. Hohmann J,
    9. Szabo M,
    10. Tanács L,
    11. Molnár P,
    12. Deli J,
    13. Krenn L,
    14. Kawase M,
    15. Wakabayashi H,
    16. Kurihara T,
    17. Shirataki Y,
    18. Sakagami H,
    19. Motohashi N,
    20. Didiziapetris R
    : Multidrug resistance reversal on cancer cells by selected carotenoids, flavovoids and anthocyanins. In: Bioactive Heterocycles VI. Berlin/Heidelberg, Germany: Springer, pp. 133-159, 2008.
  17. ↵
    1. Martins M,
    2. Ordway D,
    3. Kristiansen M,
    4. Viveiros M,
    5. Leandro C,
    6. Molnar J,
    7. Amaral L
    : Inhibition of the Carpobrotus edulis methanol extract on the growth of phagocytosed multidrug-resistant Mycobacterium tuberculosis and methicillin-resistant Staphylococcus aureus. Fitoterapia 76: 96-99, 2005.
    OpenUrlPubMed
  18. ↵
    1. Ordway D,
    2. Hohmann J,
    3. Viveiros M,
    4. Viveiros A,
    5. Molnar J,
    6. Leandro C,
    7. Arroz MJ,
    8. Grácio MA,
    9. Amaral L
    : Carpobrotus edulis methanol extract inhibits the MDR efflux pumps, enhances killing of phagocytosed S. aureus and promotes immune modulation. Phytother Res 15: 512-519, 2003.
    OpenUrl
  19. ↵
    1. Suehs CM,
    2. Affre L,
    3. Médail F
    : Invasion dynamics of two alien Carpobrotus (Aizoaceae) taxa on a Mediterranean island: I. Genetic diversity and introgression. Heredity 92: 31-40, 2004.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Watt E,
    2. Pretorius JC
    : Purification and identification of active antibacterial components in Carpobrotus edulis. J Ethnopharmacol 76: 87-91, 2001.
    OpenUrlPubMed
  21. ↵
    1. Underwood EC,
    2. Ustin SL,
    3. Ramirez CM
    : A comparison of spatial and spectral image resolutions for mapping invasive plants in coastal California. Environ Manage 39: 63-83, 2007.
    OpenUrlPubMed
  22. ↵
    1. Mathabe MC,
    2. Nikolova RV,
    3. Lall N,
    4. Nyazema NZ
    : Antibacterial activities of medicinal plants used for treatment of diarrhoea in Limpopo Province, South Africa. J Ethnopharmacol 105: 286-293, 2006.
    OpenUrlCrossRefPubMed
    1. Scott G,
    2. Hewett ML
    : Pioneers in ethnopharmacology: The Dutch East India Company (VOC) at the Cape from 1650 to 1800. J Ethnopharmacol 115: 339-360, 2008.
    OpenUrlPubMed
  23. ↵
    1. Springfield EP,
    2. Amabeoku G,
    3. Weitz F,
    4. Mabusela W,
    5. Johnson Q
    : An assessment of two Carpobrotus species extracts as potential antimicrobial agents. Phytomedicine 10: 434-439, 2003.
    OpenUrlPubMed
  24. ↵
    1. Thring TSA,
    2. Weitz FM
    : Medicinal plant use in the Bredasdorp/Elim region of the Southern Overberg in the Western Cape Province of South Africa. J Ethnopharmacol 103: 261-275, 2006.
    OpenUrlPubMed
  25. ↵
    1. Pastan I,
    2. Gottesman MM,
    3. Ueda K,
    4. Lovelace E,
    5. Rutherford AV,
    6. Willingham MC
    : A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. PNAS USA 85: 4486-4490, 1988.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Choi K,
    2. Frommel TO,
    3. Stern RK,
    4. Perez CF,
    5. Kriegler M,
    6. Tsuruo T,
    7. Roninson IB
    : Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. PNAS USA 88: 7386-7390, 1991.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Mosmann T
    : Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kars MD,
    2. Iseri OD,
    3. Gündüz U,
    4. Ural AU,
    5. Arpaci F,
    6. Molnar J
    : Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26: 4559-4568, 2006.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Spengler G,
    2. Viveiros M,
    3. Martins M,
    4. Rodriguez L,
    5. Martins A,
    6. Molnar J,
    7. Couto I,
    8. Amaral L
    : Demonstration of the activity of P-glycoprotein by a semi-automated fluorometric method. Anticancer Res 29: 2173-2177, 2009.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Kushiro T,
    2. Shibuya M,
    3. Ebizuka Y
    : Beta-amyrin synthase-cloning of oxidosqualene cyclase that catalyzes the formation of the most popular triterpene among higher plants. Eur J Biochem 256: 238-244, 1998.
    OpenUrlPubMed
  31. ↵
    1. Agerbirk N,
    2. Olsen CE,
    3. Bibby BM,
    4. Frandsen HO,
    5. Brown LD,
    6. Nielsen JK,
    7. Renwick JA
    : A saponin correlated with variable resistance of Barbarea vulgaris to the Diamondback Moth Plutella xylostella. J Chem Ecol 29: 1417-1433, 2003.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Mahato SB,
    2. Kundu AP
    : 13C NMR spectra of pentacyclic triterpenoids – A compilation and some salient features. Phytochemistry 37: 1517-1575, 1994.
    OpenUrlCrossRef
  33. ↵
    1. Siddiqui S,
    2. Mahmood T,
    3. Siddiqui BS,
    4. Faizi S
    : Two new tetranortriterpenoids from Azadirachta indica. J Nat Prod 49: 1068-1073, 2004.
    OpenUrl
  34. ↵
    1. Sakano Y,
    2. Mutsuga M,
    3. Tanaka R,
    4. Suganuma H,
    5. Inakuma T,
    6. Toyoda M,
    7. Goda Y,
    8. Shibuya M,
    9. Ebizuka Y
    : Inhibition of human lanosteri synthase by the constituents of Colocasia esculenta (Taro). Biol Pharm Bull 28: 299-304, 2005.
    OpenUrlPubMed
  35. ↵
    1. Bilia AR,
    2. Morelli I,
    3. Hamburger M,
    4. Hostettmann K
    : Flavans and A-type proanthocyanidins from Prunus prostrata. Phytochemistry 43: 887-892, 1996.
    OpenUrl
  36. ↵
    1. Chung M-I,
    2. Lai M-H,
    3. Yen M-H,
    4. Wu R-R,
    5. Lin C-N
    : Phenolics from Hypericum geminiflorum. Phytochemistry 44: 943-947, 1997.
    OpenUrl
  37. ↵
    1. Cui CB,
    2. Tezuka Y,
    3. Kikuchi T,
    4. Nakano H,
    5. Tamaoki T,
    6. Park JH
    : Constituents of a fern, Davallia mariesii Moore. II. Identification and 1H- and 13C-nuclear magnetic resonance spectra of procyanidin B-5, epicatechin-(4α-8)-epicatechin-(4α-6)-epicatechin, and epicatechin-(4α-6)–epicatechin-(4α-8)-epicatechin-(4α-6)-epicatechin. Chem Pharm Bull (Tokyo) 40: 889-898, 1992.
    OpenUrlPubMed
  38. ↵
    1. Lorian V
    : Antibiotics in Laboratory Medicine. 3rd edition. Baltimore: Williams &Wilkins, 2009.
  39. ↵
    1. Howells LM,
    2. Moiseeva EP,
    3. Neal CP,
    4. Foreman BE,
    5. Andreadi CK,
    6. Sun YY,
    7. Hudson EA,
    8. Manson MM
    : Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin 28: 1274-1304, 2007.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Zessner H,
    2. Pan L,
    3. Will F,
    4. Klimo K,
    5. Knauft J,
    6. Niewöhner R,
    7. Hümmer W,
    8. Owen R,
    9. Richling E,
    10. Frank N,
    11. Schreier P,
    12. Becker H,
    13. Gerhauser C
    : Fractionation of polyphenol-enriched apple juice extracts to identify constituents with cancer chemopreventive potential. Mol Nutr Food Res 52(Suppl 1): S28-S44, 2008.
    OpenUrlPubMed
  41. ↵
    1. Souccar C,
    2. Cysneiros RM,
    3. Tanae MM,
    4. Torres LMB,
    5. Lima-Landman MTR,
    6. Lapa AJ
    : Inhibition of gastric acid secretion by a standardized aqueous extract of Cecropia glaziovii Sneth and underlying mechanism. Phytomedicine 15: 462-469, 2008.
    OpenUrlPubMed
  42. ↵
    1. Kitagawa S,
    2. Nabekura T,
    3. Kamiyama S
    : Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 56: 1001-1005, 2004.
    OpenUrlPubMed
  43. ↵
    1. He S,
    2. Sun G,
    3. Pan D
    : Red wine polyphenols for cancer prevention. Int J Mol Sci 9: 842-853, 2008.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 30 (3)
Anticancer Research
Vol. 30, Issue 3
March 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Constituents of Carpobrotus edulis Inhibit P-Glycoprotein of MDR1-transfected Mouse Lymphoma Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 10 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Constituents of Carpobrotus edulis Inhibit P-Glycoprotein of MDR1-transfected Mouse Lymphoma Cells
A. MARTINS, A. VASAS, ZS. SCHELZ, M. VIVEIROS, J. MOLNÁR, J. HOHMANN, L. AMARAL
Anticancer Research Mar 2010, 30 (3) 829-835;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Constituents of Carpobrotus edulis Inhibit P-Glycoprotein of MDR1-transfected Mouse Lymphoma Cells
A. MARTINS, A. VASAS, ZS. SCHELZ, M. VIVEIROS, J. MOLNÁR, J. HOHMANN, L. AMARAL
Anticancer Research Mar 2010, 30 (3) 829-835;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Identification of Important Compounds Isolated from Natural Sources that Have Activity Against Multidrug-resistant Cancer Cell Lines: Effects on Proliferation, Apoptotic Mechanism and the Efflux Pump Responsible for Multi-resistance Phenotype
  • Google Scholar

More in this TOC Section

  • Cytotoxic and Metalloproteinase-inhibitory Effects of Ellagic Acid Against Oral Squamous Cell Carcinoma
  • Artogomezianone Inhibits EGFR and Promotes Apoptosis in Non-small Cell Lung Cancer Cells
  • Resveratrol Derivatives Inhibit Pro-survival Akt Signaling Pathway in Lung Cancer
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire